RxDoctor Payments Data

Jia Li Duan, DO

Family Medicine · Perry, FLNPI 1629647326

Payments from drug & device makers

$1,328in general payments, 2019–2025

Across 59 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$394
  • Novo Nordisk$177
  • AbbVie$114
  • Novartis$106
  • Amgen$100
  • Phathom Pharmaceuticals, Inc.$88
  • plus $348 from 10 others

What the payments were for

  • Food & beverage$1,328100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,328 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$79,409
Medicare patients
179
Services billed
1,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$44,744
MounjaroTirzepatide37$38,862
FarxigaDapagliflozin Propanediol32$35,090
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$33,893
OzempicSemaglutide28$27,353
JardianceEmpagliflozin11$13,229
Repatha SureclickEvolocumab19$12,334
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,474
Humalog Kwikpen U-100Insulin Lispro11$1,829
Divalproex Sodium ErDivalproex Sodium24$1,253
Albuterol Sulfate HfaAlbuterol Sulfate54$1,228
Fluticasone Propionate65$1,178
Atorvastatin Calcium156$1,138
Omeprazole57$1,068
Rosuvastatin Calcium89$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$394$46,56450 claims
PfizerEliquis$13$44,74442 claims
GSKTrelegy Ellipta$76$33,89344 claims
Novo NordiskOzempic$177$27,35328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Perry

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →